Your browser doesn't support javascript.
loading
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama, B; Arranz Arija, J A; Rodríguez Sánchez, A; Pinto Marín, A; Borrega García, P; Castellano Gaunas, D E; Rubio Romero, G; Maximiano Alonso, C; Villa Guzmán, J C; Puertas Álvarez, J L; Chirivella González, I; Méndez Vidal, M J; Juan Fita, M J; León-Mateos, L; Lázaro Quintela, M; García Domínguez, R; Jurado García, J M; Vélez de Mendizábal, E; Lambea Sorrosal, J J; García Carbonero, I; González del Alba, A; Suárez Rodríguez, C; Jiménez Gallego, P; Meana García, J A; García Marrero, R D; Gajate Borau, P; Santander Lobera, C; Molins Palau, C; López Brea, M; Fernández Parra, E M; Reig Torras, O; Basterretxea Badiola, L; Vázquez Estévez, S; González Larriba, J L.
Afiliação
  • Pérez-Valderrama B; Department of Medical Oncology, Virgen del Rocío University Hospitals, Sevilla bperezv@gmail.com.
  • Arranz Arija JA; Department of Medical Oncology, Gregorio Marañón General University Hospital, Madrid.
  • Rodríguez Sánchez A; Department of Medical Oncology, University Hospital of León, Leon.
  • Pinto Marín A; Department of Medical Oncology, La Paz University Hospital, Madrid.
  • Borrega García P; Department of Medical Oncology, San Pedro de Alcántara Hospital, Cáceres.
  • Castellano Gaunas DE; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid.
  • Rubio Romero G; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid.
  • Maximiano Alonso C; Department of Medical Oncology, Puerta de Hierro University Hospital, Majadahonda (Madrid).
  • Villa Guzmán JC; Department of Medical Oncology, General University Hospital of Ciudad Real, Ciudad Real.
  • Puertas Álvarez JL; Department of Medical Oncology, Rio Hortega University Hospital, Valladolid.
  • Chirivella González I; Department of Medical Oncology, University Hospital of Valencia, Valencia.
  • Méndez Vidal MJ; Department of Medical Oncology, Reina Sofía University Hospital, Córdoba.
  • Juan Fita MJ; Department of Medical Oncology, Valencian Institute of Oncology, Valencia.
  • León-Mateos L; Department of Medical Oncology, Santiago University Hospital Complex, Santiago de Compostela.
  • Lázaro Quintela M; Department of Medical Oncology, University Hospital Complex of Vigo, Vigo.
  • García Domínguez R; Department of Medical Oncology, Clinic University Hospital of Salamanca, Salamanca.
  • Jurado García JM; Department of Medical Oncology, San Cecilio University Hospital, Granada.
  • Vélez de Mendizábal E; Department of Medical Oncology, San Pedro Hospital, Logroño.
  • Lambea Sorrosal JJ; Department of Medical Oncology, Lozano Blesa University Hospital, Zaragoza.
  • García Carbonero I; Department of Medical Oncology, Virgen de la Salud Hospital, Toledo.
  • González del Alba A; Department of Medical Oncology, Son Espases University Hospital, Palma de Mallorca.
  • Suárez Rodríguez C; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona.
  • Jiménez Gallego P; Department of Medical Oncology, Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria.
  • Meana García JA; Department of Medical Oncology, University Hospital of Alicante, Alicante.
  • García Marrero RD; Department of Medical Oncology, University Hospital of Canarias, San Cristóbal de La Laguna (Santa Cruz de Tenerife).
  • Gajate Borau P; Department of Medical Oncology, Quirón University Hospital, Madrid.
  • Santander Lobera C; Department of Medical Oncology, Miguel Servet University Hospital, Zaragoza.
  • Molins Palau C; Department of Medical Oncology, Doctor Peset University Hospital, Valencia.
  • López Brea M; Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander.
  • Fernández Parra EM; Department of Medical Oncology, Nuestra Señora de Valme University Hospital, Sevilla.
  • Reig Torras O; Department of Medical Oncology, Clinic University Hospital of Barcelona, Barcelona.
  • Basterretxea Badiola L; Department of Medical Oncology, Donostia University Hospital, San Sebastián.
  • Vázquez Estévez S; Department of Medical Oncology, Lucus Augusti University Hospital, Lugo.
  • González Larriba JL; Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain.
Ann Oncol ; 27(4): 706-11, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26658889
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Pirimidinas / Sulfonamidas / Carcinoma de Células Renais / Terapia de Alvo Molecular Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prognóstico / Pirimidinas / Sulfonamidas / Carcinoma de Células Renais / Terapia de Alvo Molecular Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article